חזרה לתוצאות החיפוש

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

ישראלמגייס משתתפיםPHASE3

מצבים רפואיים

Systemic Lupus Erythematosus

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Pinnacle Research Group Llc, Anniston, Alabama, United States

    Contact: Study coordinator (Ruby Fields) · rfields@pinnacletrials.com · 256-236-0055
    Contact: Principal Investigator (Vishala L Chindalore)

  • Providence Medical Center, Burbank, California, United States

    Contact: Study coordinator (Sandra Figueroa) · Sandra.Figueroa@providence.org · 818-869-7067
    Contact: Principal Investigator (Sue Chung)

  • Advanced Medical Research, La Palma, California, United States

    Contact: Study coordinator (Alejandro Merazo) · amerazo@advmedresearch.com · 714-752-6587
    Contact: Principal Investigator (Gerald Ho)

  • Millennium Clinical Trials, Westlake Village, California, United States

  • University of Colorado Denver, Aurora, Colorado, United States

    Contact: Study coordinator (Chong Pedrick) · chong.pedrick@cuanschutz.edu
    Contact: Principal Investigator (Christopher Striebich)

  • Clinical Res Of W Florida, Clearwater, Florida, United States

    Contact: Study coordinator (Jessica Mayfield) · JMayfield@crwf.com · 727-466-0078
    Contact: Principal Investigator (Robert Levin)

  • GNP Research, Cooper City, Florida, United States

    Contact: Study coordinator (Melissa Pierce) · melissa@gnpresearch.com · 754-248-3589
    Contact: Principal Investigator (Mark Jaffe)

  • IRIS Research and Development, Plantation, Florida, United States

    Contact: Study coordinator (Jhon Galindo) · jgalindo@irisrheumatology.com · 954-476-2338
    Contact: Principal Investigator (Guillermo Valenzuela)

  • Clinical Research of West Florida Inc, Tampa, Florida, United States

    Contact: Study coordinator (Abby Carlson) · ACarlson@crwf.com · 813-870-1292
    Contact: Principal Investigator (John Carter)

  • Parris and Associates Rheumatology, Lawrenceville, Georgia, United States

    Contact: Study coordinator (Mannai Coutermarsh) · m.coutermarsh@parrisandassociates.net · +17709621616#8334
    Contact: Principal Investigator (Glenn Parris)

  • Robert A Hozman MD SC, Skokie, Illinois, United States

    Contact: Study coordinator (Patrycja Kalwajtys) · pkalwajtys@cisresearch.com · 847-727-2743
    Contact: Principal Investigator (Robert Hozman)

  • Willow Rheumatology Wellness, Willowbrook, Illinois, United States

    Contact: Study coordinator (Lubna Ali) · lali@willowrheum.com
    Contact: Principal Investigator (Angela R Crowley)

  • Accurate Clinical Research, Lake Charles, Louisiana, United States

    Contact: Study coordinator (Machell Broussard) · mbroussard@accurateclinicalresearch.com
    Contact: Principal Investigator (Enrique Mendez)

  • University Of Maryland, Baltimore, Maryland, United States

  • Henry Ford Health, Detroit, Michigan, United States

    Contact: Study coordinator (Jenna Hudy) · jhudy1@hfhs.org · 313-916-1984
    Contact: Principal Investigator (Alireza Meysami)

  • Ahmed Arif Medical Research Center, Grand Blanc, Michigan, United States

    Contact: Study coordinator (Iman Abdelrahman) · iman@aamrc.net · 810-953-8700
    Contact: Principal Investigator (Ali Karrar)

  • Paramount Med Rsrch and Consult LLC, Middleburg Heights, Ohio, United States

    Contact: Study coordinator (Denine Ryan) · deniner64@gmail.com · 440-891-9395
    Contact: Principal Investigator (Isam Diab)

  • West Tennessee Research Institute, Jackson, Tennessee, United States

    Contact: Study coordinator (Abbie Hinton) · ahinton@arthritisclinic.org · 731-633-0119
    Contact: Principal Investigator (Jacob A Aelion)

  • Shelby Research LLC, Memphis, Tennessee, United States

    Contact: Study coordinator (Suvarna Konangula) · shelbyres1999@outlook.com · 901-681-9670
    Contact: Principal Investigator (Ramesh C Gupta)

  • Novel Research LLC, Bellaire, Texas, United States

  • Accurate Clinical Research, League City, Texas, United States

    Contact: Study coordinator (Mariela Martinez) · mmartinez@accurateclinicalresearch.com
    Contact: Principal Investigator (Sabeen Najam)

  • Epic Medical Research, Red Oak, Texas, United States

    Contact: Study coordinator (Harshini Potluri) · hpotluri@epicmedresearch.com · 469-206-2642
    Contact: Principal Investigator (Sunny Patel)

  • Novartis Investigative Site, La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site, Quilmes, Buenos Aires, Argentina

  • Novartis Investigative Site, San Miguel, Buenos Aires, Argentina

  • Novartis Investigative Site, San Miguel, Tucumán Province, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, San Miguel de Tucumán, Argentina

  • Novartis Investigative Site, Maroochydore, Queensland, Australia

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site, Niterói, Rio de Janeiro, Brazil

  • Novartis Investigative Site, Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site, Barretos, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Salvador, Brazil

  • Novartis Investigative Site, Plovdiv, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Vancouver, British Columbia, Canada

  • Novartis Investigative Site, Rimouski, Quebec, Canada

  • Novartis Investigative Site, Valdivia, Los Ríos Region, Chile

  • Novartis Investigative Site, Santiago, RM, Chile

  • Novartis Investigative Site, Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Shantou, Guangdong, China

  • Novartis Investigative Site, Nanjing, Jiangsu, China

  • Novartis Investigative Site, Suzhou, Jiangsu, China

  • Novartis Investigative Site, Nanchang, Jiangxi, China

  • Novartis Investigative Site, Pingxiang, Jiangxi, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Linyi, Shandong, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Ürümqi, Xinjiang, China

  • Novartis Investigative Site, Ningbo, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Xinxiang, China

  • Novartis Investigative Site, Medellín, Antioquia, Colombia

  • Novartis Investigative Site, Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site, Chía, Cundinamarca, Colombia

  • Novartis Investigative Site, Bucaramanga, Santander Department, Colombia

  • Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site, Bogotá, Colombia

  • Novartis Investigative Site, Brno, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Uherské Hradiště, Czechia

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Leipzig, Saxony, Germany

  • Novartis Investigative Site, Guatemala City, Guatemala

  • Novartis Investigative Site, Székesfehérvár, Fejér, Hungary

  • Novartis Investigative Site, Gyula, Hungary

  • Novartis Investigative Site, Zalaegerszeg, Hungary

  • Novartis Investigative Site, Ahmedabad, Gujarat, India

  • Novartis Investigative Site, Ahmedabad, Gujarat, India

  • Novartis Investigative Site, Kozhikode, Kerala, India

  • Novartis Investigative Site, Kolhāpur, Maharashtra, India

  • Novartis Investigative Site, Nagpur, Maharashtra, India

  • Novartis Investigative Site, Nashik, Maharashtra, India

  • Novartis Investigative Site, Pune, Maharashtra, India

  • Novartis Investigative Site, New Delhi, India

  • Novartis Investigative Site, New Delhi, India

  • Novartis Investigative Site, Pisa, PI, Italy

  • Novartis Investigative Site, Torino, TO, Italy

  • Novartis Investigative Site, Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site, Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan

  • Novartis Investigative Site, Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site, Fuchū, Tokyo, Japan

  • Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site, Ipoh, Perak, Malaysia

  • Novartis Investigative Site, León, Guanajuato, Mexico

  • Novartis Investigative Site, Guadalajara, Jalisco, Mexico

  • Novartis Investigative Site, Mexico City, Mexico City, Mexico

  • Novartis Investigative Site, Morelia, Michoacán, Mexico

  • Novartis Investigative Site, Mérida, Yucatán, Mexico

  • Novartis Investigative Site, México, Mexico

  • Novartis Investigative Site, Wroclaw, Lower Silesian Voivodeship, Poland

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Bytom, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Braga, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Cluj-Napoca, Cluj, Romania

  • Novartis Investigative Site, Brasov, Romania

  • Novartis Investigative Site, Bucharest, Romania

  • Novartis Investigative Site, Košice, Slovakia

  • Novartis Investigative Site, Pretoria, Gauteng, South Africa

  • Novartis Investigative Site, Cape Town, Western Cape, South Africa

  • Novartis Investigative Site, Cape Town, Western Cape, South Africa

  • Novartis Investigative Site, Somerset West, Western Cape, South Africa

  • Novartis Investigative Site, Umhlanga, South Africa

  • Novartis Investigative Site, Gwangju, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, Badalona, Barcelona, Spain

  • Novartis Investigative Site, Santander, Cantabria, Spain

  • Novartis Investigative Site, Barcelona, Catalonia, Spain

  • Novartis Investigative Site, San Sebastian Reyes, Madrid, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

מובילי המחקר

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)